Scientists discover why this deadly lung cancer keeps coming back

A research team led by Professor Dr. Silvia von Karstedt (Translational Genomics, CECAD Cluster of Excellence on Aging Research, and Center for Molecular Medicine Cologne — CMMC) has identified a previously unknown process that may explain why this cancer behaves so aggressively. Their findings, published in Nature Communications, come from a study titled “Lack of Caspase 8 Directs Neuronal Progenitor-like reprogramming and Small Cell Lung Cancer Progression.”

Cancer Cells With Neuron-Like Traits

Unlike many other epithelial cancers, SCLC shares characteristics with nerve cells. One key feature is the absence of caspase-8, a protein that plays an important role in programmed, non-inflammatory cell-death (apoptosis). This process helps the body remove damaged or abnormal cells and is essential for maintaining healthy tissue.

Inflammatory Cell Death and Immune Suppression

To better replicate how SCLC develops in humans, the researchers created a genetically engineered mouse model that lacks caspase-8. Using this model, they uncovered a chain reaction triggered by the absence of this protein. “The absence of caspase-8 leads to a type of inflammatory cell death called necroptosis that creates a hostile, inflamed environment even before tumors fully form” explains von Karstedt. “We were also intrigued to find that pre-tumoral necroptosis can in fact promote cancer by conditioning the immune system,” she continues.

This inflammatory environment weakens the body’s natural defenses by suppressing its anti-cancer immune response, making it harder for immune cells to attack cancerous threats. As a result, the conditions become more favorable for tumor growth and tumour metastasis. The researchers also found that inflammation pushes cancer cells into a more immature, neuron-like state, which enhances their ability to spread and is linked to relapse.

Implications for Future Treatments and Early Detection

It is still unclear whether this type of pre-tumoral inflammation occurs in human patients. However, the study highlights a key mechanism that may drive both the aggressiveness of SCLC and its tendency to return after treatment. These insights could help guide the development of more effective therapies and improve early detection strategies.

This research was supported by the German Research Foundation within Collaborative Research Centre (CRC) 1399 “Mechanisms of drug sensitivity and resistance in small cell lung cancer.”